S. Korean health authority announced on the 20th that it has confirmed the efficacy of Celltrion's COVID-19 antibody treatment ‘Regkirona’ to slow down the progress to severe through the clinical trials on patients with COVID-19 Delta variant.
The Korea Disease Control and Prevention Agency (KDCA) held a regular briefing and announced that it conducted clinical trial on 626 high-risk patients with mild to moderate COVID-19 at National Institute of Health Center for Infectious Diseases Research from June to September last year and analyzed their progression to severe COVID-19.
An official from the KDCA said, “Most of the participating patients were with Delta variant, and it was confirmed that Regkirona reduced the severe progression of patients. Among the patients with confirmed Delta variant, 486 patients were treated by Regkirona, of which 5.6% (27 patients) became severely ill.”
He added, “On the other hand, Among 140 patients in the symptomatic therapy group, 15% (21 patients) had progression to severe COVID-19.” The symptomatic therapy refers to a treatment that eases the symptoms such as fever without addressing the basic cause of the disease.
Global Economic Reporter Tae-hyung Kim ; Translate by Gounee Yang